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ABSTRACT 
 
 
AYESHA SWARN: Effectiveness of a New Protocol for Caries Management in High 
Risk Patients 
(Under the direction of André V. Ritter) 
 
 
Objective: To (1) examine the effectiveness of a home-care protocol (CariFree®, 
Oral Biotech, Albany, OR) in reducing caries risk in high-risk adults compared to 
conventional oral hygiene measures and (2) determine the agreement between a chairside 
ATP bioluminescence test (CariScreen) and laboratory Mutans Streptococci (MS) counts 
(CFU/mL of saliva). Methods: 24 high caries risk subjects were randomly assigned to 
intervention (CariFree treatment protocol) or control (brush twice and floss once daily) 
groups. Plaque and stimulated saliva samples were evaluated at baseline, 1 and 3 months 
for ATP bioluminescence, buffering capacity, Lactobacillus and MS counts. Results: At 
all evaluation times, no statistically significant difference was observed within groups or 
between the intervention and control group. The CariScreen scores showed poor 
correlation with MS counts. Conclusions: The CariFree protocol did not reduce caries 
risk of high-risk adults compared to traditional home-care. There was poor correlation 
between the CariScreen test and MS counts. 
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1 INTRODUCTION 
 
The global burden of oral disease and dental caries has been steadily rising even 
as improved and novel tools for reconstructing damaged dentition are rapidly evolving. 
Approximately 90% of the population in developed countries is affected by this 
preventable  disease[1]. Recent trends suggest an increase in incidence of dental caries 
amongst specific populations in the US [2]. Dentistry has traditionally managed dental 
caries through a “drill and fill” approach. This approach has served well to restore 
function and esthetics, however has failed to prevent the incidence of new carious 
lesions. The World Health Organization (WHO) through the Sixtieth World Health 
Assembly has passed a resolution that advocates integration of prevention and early 
intervention measures of dental caries for all the member nations [3]. Over the past 
decades, the health care organizations in many nations have still not implemented 
mandatory comprehensive caries prevention into routine dental practice [4]. The 
increased burden of the disease worldwide may also be attributed to the fact that dentists 
as a majority both in dental schools and practices still focus on the treatment rather than 
prevention of the disease.  
Caries prevention and treatment based on an analysis of the presence or absence 
of risk factors is advocated by the American Dental Association. Caries risk assessment 
through risk indicators (diet, host and microbiological) was first elaborated upon in a 
supplement by JADA in 1995 [5]. An accurate, valid and efficient caries risk assessment 
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model must consistently identify high caries risk patients. These models base the caries 
risk analysis on a number of factors- both clinical and biological. Caries management by 
risk assessment (CAMBRA) is a system that focuses on treating and preventing the cause 
of the disease at an early stage, rather than waiting until it causes irreversible damage to 
tooth [6-8]. This system is being advocated as a standard of care for practicing dentistry 
within the dental community.  
Studies comparing the appropriate preventive and interventional protocols for 
caries management following a caries risk assessment have been used for the validation 
of caries risk assessment models. A systematic review conducted on selected caries 
prevention methods concluded that enough evidence does not exist to determine the 
efficacy of new methods of caries prevention and management[9]. A recommendation 
has been made to increase the number of studies examining prevention among high risk 
individuals.  
The purpose of this thesis is to compare a new protocol for caries management 
(CariFree®, Oral BioTech, Albany, OR) to conventional oral hygiene measures for 
treatment of high caries risk subjects. CariFree is a new caries assessment and treatment 
model based on CAMBRA and uses fluoride, xylitol and pH alteration for decreasing the 
individual’s risk for caries [10, 11].  
The organization of this thesis is as follows. A description of the Objectives of 
this research is followed by a summary of relevant literature. The Materials and Methods 
section follows the review and describes the study design, materials used and data 
collection instruments and sequence. The Results and Discussion sections illustrate the 
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outcomes of the study followed by a section highlighting the Conclusions drawn from the 
study outcomes. 
   
 
 
 
 
 
 
2 OBJECTIVES 
 
 
The purpose of this study was to examine the effectiveness of a new protocol for 
caries management in reducing caries risk when used in high risk adults.  The treatment 
protocol consisted of using home care oral hygiene products (CariFree) for a period of 90 
days.  The study hypothesis was that the CariFree Treatment Protocol is more effective in 
reducing caries risk than conventional oral hygiene measures after a 90 day regimen in 
high risk adults.  
2.1 Specific Aims 
 
2.1.1 Primary Aim 
To examine the effectiveness of a new home care protocol in reducing caries risk 
in high risk adults when compared with conventional (or usual) home care.  
2.1.2 Secondary Aim 
To determine the agreement between a chairside ATP bioluminescence test 
(CariScreen) and a laboratory-based salivary Streptococcal Mutans count (CFU/mL of 
saliva). 
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2.2 Hypotheses  
Primary Aim: The use of CariFree home care protocol will reduce the caries risk 
in high caries risk adults after a 90 day regimen in comparison with those continuing with 
conventional oral hygiene practices. 
Secondary Aim: A good agreement exists between the ATP bioluminescence test 
and Streptococcal mutans counts. 
 
   
 
 
 
 
 
 
3  LITERATURE REVIEW 
 
Research over the past 50 years has established dental caries as a bacterial based 
chronic infectious disease. It presents with a time dependent complex etiology involving 
tooth substrate, bacterial flora, presence of a fermentable carbohydrate source, and access 
to minerals namely calcium, phosphate and fluoride. The bacteria present in the plaque or 
oral biofilm adherent to the tooth surface ferment carbohydrates contained in our diet and 
release acids. These acids diffuse into enamel and dentin, dissolving the mineral 
components of the tooth. Under normal conditions the mineral lattice of the tooth behaves 
like a sieve and free ions such as Ca
++
 and PO4
-
 present in the saliva migrate back into the 
lattice of the tooth once the acid is buffered by the saliva.  
 While this process of demineralization and remineralization is constantly 
occurring underneath the oral biofilm, under special conditions, a sub-surface carious 
lesion or break in the tooth surface can develop. These special conditions or risk markers 
are numerous and may include presence of acidogenic bacteria, reduced salivary function 
coupled with frequent acid attack, and presence of oral restorations or devices promoting 
biofilm build-up [12].The following review attempts to look at the current concepts and 
known risk markers for caries and how they interplay with one another to determine the 
caries risk of an individual. The current accepted treatment protocols for managing 
patients with high caries risk shall also be reviewed subsequently. 
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3.1 Caries Disease Process  
 
Specific strains of bacteria such as Mutans Streptococcus (MS) and Lactobacilli 
(LB), associated with the initiation and progression of the disease, have consistently been 
isolated in oral plaque and salivary samples. These two strains MS and LB are aciduric 
and acidogenic with pH varying from 3.8-4.8.  For many years it has been considered that 
the low pH products of metabolism from these two strains result in acid dissolution of 
tooth structure and further progression of disease [4, 13-15]. More recent research have 
suggested that while these two strains may be considered as markers for the disease, there 
are additional groups of organisms that are involved with the progression of the 
disease[15, 16]. Since the traits associated with cariogenicity are not associated with a 
single species of bacteria, it is but evident that measures to combat caries initiation and 
progression must include other intervention factors.  
Caries must be viewed as a disease resulting from changes in the ecology of 
bacterial communities in the mouth. The Keys-Venn diagram (insert figure) depicting the 
etiology of caries has been modified now to include the ecological plaque hypothesis 
[17]. Change in the environment such as carbohydrate intake and xerostomia can lead to 
these dramatic shifts in oral environment. Many studies report the correlation between 
increase in bacterial flora and presence of disease; however the balance between 
environment, plaque microflora and integrity of tooth structure is yet to be investigated 
completely [15, 16, 18, 19]. Bowden in 1984 posed pertinent questions regarding the 
nature of the environmental stresses that convert a healthy biofilm into a pathogenic 
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biofilm [20]. The additional questions arising and yet unanswered entirely are whether 
the modification of the biofilm environment reduces caries. 
Dental plaque consists of a film of polymers and bacteria over the tooth surface. 
These bacteria under stress team up and form a collective called oral biofilm which is 
attached to the tooth surface. Andre Levchenko mentions that biofilms are large 
communities organized like cities with channels for nutrients to go in and waste to go out 
[21]. The role that Mutans Streptococcus and other organisms present in biofilms play is 
continuing to unfold methodically through dedicated research. Genetic analysis using 
genotypic methods such as 16S rRNA gene sequence analysis are being increasingly 
employed for the isolation of potential pathogens [22]. Interestingly, biofilm growth has 
shown both indirect and direct influences on gene expression by oral bacterial [23]. 
Other important virulence factors being investigated are the Streptococcus Mutans 
Glucosyltransferases. The glucans produced by this enzyme released from the 
Streptococcus Mutans helps more bacteria to adhere to the tooth surface. The molecular 
structure of glucans changes when glucosyltransferases are adsorbed by a surface [24]. 
Additionally, other oral bacteria also start to produce glucans once exposed to this 
enzyme [25]. The multiplication of bacteria and subsequent formation of a complex 
extracellular matrix results in a stable and resistant shield around the biofilm. This plays a 
critical role in preventing exogenous pathogenic species from colonizing the mouth 
(colonization resistance) [26]. Bacteria growing in the biofilm also start developing 
resistance to anti- microbial agents [27]. In 1996 it was demonstrated that a 24 h plaque 
sample required multiple times the minimum concentration of chlorhexidine to eliminate 
S. Sanguinis, and an even higher concentration is required by a 72 h sample [28]. The 
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reasons for the increased biofilm tolerance to antimicrobials were elaborated upon by 
Stewart et al. They hypothesized poor antibiotic penetration, nutrient limitation and slow 
growth, adaptive stress responses, and formation of persister cells as reasons for the 
heightened antibiotic resistance [29]. Other confounding features of the biofilm include 
the heterogeneous distribution of the pH within the structure of the biofilm [30]. This 
facilitates the growth of different genera of bacteria within the community, which 
otherwise do not coexist. Consequently an extremely tenacious bio-community 
impervious to antibiotics and permanent disruption develops around teeth in susceptible 
individuals. Meanwhile, the persistent aciduric and acidogenic colonies present in the 
underbelly of this multilayered film, continue to cause acid demineralization of the tooth 
structure in the absence of the protective functions of saliva. 
The process of demineralization of the tooth by the aciduric and acidogenic 
bacteria in the biofilm can be arrested by the presence of saliva containing acid buffers 
and antimicrobial enzymes in the initial stages [19, 31, 32]. However, continued acid 
attack coupled with poor oral hygiene and dietary habits could result in active disease. 
Both quality and quantity of saliva is important to maintain the oral structures. Since 
cariogenic substances are constantly introduced into the oral cavity, saliva aids in diluting 
the acid and sugars and providing oral clearance. Sites in the mouth closer to orifices of 
salivary ducts have a faster clearance rate compared to other areas like mandibular buccal 
surfaces making them more susceptible to biofilm colonization. The residual volume of 
saliva left over after swallowing forms a thin film averaging around 0.1mm thick and 
develops a concentrated reservoir of sucrose after a meal. This varies based on location, 
tooth morphology and sex of the patient [33].  A correlation has been noted between the 
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salivary clearance of a patient and the pH changes of plaque. The Stephan Curve 
describes the change in dental plaque pH in response to a challenge. The slopes of 
Stephan curves vary for slow and fast clearance rates [33]. As the pH of the biofilm 
becomes more acidic, only those bacteria that can survive in a low pH grow. These 
bacteria are responsible for the demineralization of teeth and the caries process. 
Bradshaw, McKee, and Marsh in 1989 described the effects of carbohydrate pulses and 
pH on population shifts within oral microbial communities [34]. The results of their 
experiments demonstrated that in presence of sugar, the SM and LB species multiplied 
only in the media in which pH changes were allowed to occur (Figure. 1). Hence control 
over the plaque pH through efficient buffering would seem key in preventing the caries 
process.  
Salivary gland hypofunction is also contributory towards caries risk. While 
hyposalivation is an objective measure of the amount of salivary production and 
xerostomia is a subjective feeling of dry mouth, both terminologies are often used in 
place of each other erroneously. Average normal values of salivary flow rates are 
1.5ml/min stimulated and 0.3ml/min unstimulated. However these values have a large 
variation based on age and sex. To be classified as abnormally low, the salivary flow rate 
for saliva must be equal to or less than 0.1ml/min for unstimulated and 0.5-0.7ml/min for 
stimulated. Nonetheless, the symptoms of dry mouth may be experienced even at higher 
salivary rates. Some of the common causes of hyposalivation include medication, 
radiation therapy, immune deficiencies, and salivary gland inflammations. 
 Quality of saliva is dependent on the protein content, viscosity, pH and buffering 
capacity. Saliva carries antifungal and antibacterial peptides; calcium, phosphate and 
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fluoride ions for potential remineralization of tooth and lubricants to keep mouth 
moist[35]. While buffering capacity of saliva is often employed as a measure of caries 
risk, the measure is not a precise assessment of the pH of the microflora within the depths 
of the biofilm. 
3.2 Caries Risk Assessment and Management 
 
Evidence based protocols for risk assessment and management of dental caries 
has gained momentum amongst the dental community in recent times [7, 36]. Caries risk 
assessment has over the past decade included a two pronged approach-evaluating 
populations and individualized risk assessment [37].  The disproportionate distribution of 
caries by race, age, geographic area and socioeconomic status submits the need for 
individualized caries risk assessment [38]. Caries predictive models for pre-school and 
school age children have been reported [39, 40]. A review of microbiological factors 
concluded that while specific bacteria may not be a reliable risk indictor for caries risk 
for individuals but might be useful while evaluating high caries risk groups [41]. The 
review goes on to suggest that SM and LB counts may be more predictive in establishing 
low caries risk more consistently than high caries risk. The past caries experience of a 
patient has been adjudged as the variable with highest predictive value by others [36, 42]. 
Due to the multifactorial nature of caries etiology, it is expected that multivariate 
approaches rather than the use of single parameters may improve caries risk prediction 
for individuals as well as groups of subjects.  
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Various attempts to group the etiological agents of the disease and caries risk 
predictors have been made in the past. For the purpose of this review, the causative 
factors which are predictive of disease but not necessarily etiologic variables are referred 
as “risk indicators”. Other terminologies include “risk factors” as causative variables. A 
recent review of the clinical studies looking at risk predictors for adult and adolescent 
dentition and out of 24 total studies found that all included past caries experience as an 
important predictor followed by “other variables”. Microbiology and host factors 
completed the list in both adults and children. While looking at root caries, the host 
factors were ranked higher than the microbiology. So the challenge is to better define 
how contributing factors interact and how this translates into a cost-effective strategy for 
disease diagnosis, prevention, and management. In a recent review on the caries risk 
assessment for prosthodontic patients, a tabulation of the most common risk factors based 
on clinical exams were presented [8].  Tables 1 and 2 present an edited version of the 
same. 
The validity of the various caries prediction models that are present to predict 
caries need to be studied in the context of their application within specific populations. 
All models are typically arithmetic calculations including a combination of the above 
mentioned risk factors and indicators. A high specificity for the model is desirable in case 
the instrument is used for a large population based survey in order to avoid false 
positives. Similarly for individual analysis it becomes critical to have a high sensitivity to 
reduce false negatives.  Based on the assessments, the subjects are classified as high, 
intermediate and low risk and the treatment protocols are then determined.  
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3.2.1 CAMBRA (Caries Management by Risk Assessment) 
CAMBRA was formed by an unofficial group called the Western CAMBRA 
Coalition and included representatives from education, research, industry, governmental 
agencies and private practitioners based in the western states of the US [43]. The 
CAMBRA risk assessment tool divides risk of developing dental caries into the following 
subdivisions [7].  
3.2.1.1 Caries risk indicators 
Visible cavities or radiographic penetration of the dentin, radiographic proximal  
enamel lesions (not in dentin), white spots on smooth surfaces, restorations last 3 years. 
3.2.1.2 Caries risk factors (Biological predisposing factors)  
Mutans Streptococcus (MS) and Lactobacillus (LB) both medium or high (by 
culture), visible heavy plaque on teeth, frequent snack (> 3x daily between meals), deep 
pits and fissures, recreational drug use, inadequate saliva flow by observation or 
measurement saliva reducing factors (medications/radiation/systemic), exposed roots , 
orthodontic appliances. 
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3.2.1.3 Caries protective factors  
 Lives/work/school fluoridated community, fluoride toothpaste at least once daily, 
fluoride toothpaste at least 2x daily, fluoride mouthrinse (0.05% NaF) daily, 5,000 ppm F 
fluoride toothpaste daily, fluoride varnish in last 6 months, office F topical in last 6 
months, chlorhexidine prescribed/used one week each of last 6 months, xylitol 
gum/lozenges 4x daily last 6 months, calcium and phosphate paste during last 6 months, 
Adequate saliva flow (> 1 ml/min stimulated).  
Figure 2 represents the interplay between the various factors. The caries balance 
must be maintained by appropriate use of therapeutic agents since surgically replacing the 
diseased part of the tooth does not decrease risk of future disease [44, 45]. The past 
experience of the disease itself being its most prominent risk indicator, an emphasis on a 
preventive approach to treat the disease needs to be investigated further. Since dental 
caries is a biofilm (or bacteria) mediated disease, the current evidence-based prevention 
methods include fluoride applications, diet modifications and good oral hygiene 
practices. 
3.3 Motivational Interviewing, Diet Modification, and Oral Hygiene Practices 
 
Sugar plays an important role in the initiation and progression of the carious 
disease process. A thorough diet analysis to isolate harmful eating patterns such as sugary 
drinks with low pH, frequent snacking and inadequate oral hygiene measures needs to be 
performed prior to initiating a caries reduction protocol and expensive restorative 
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therapy. Behavioral patterns need to be reviewed. Patient compliance is often the biggest 
factor reducing the success of caries control therapy [46]. Motivational interviewing, a 
patient-centered counseling technique, has been found to be effective in reducing caries 
in high-risk young children [47]. It was first described by Dr William Miller in 1983 in 
relation to his work with alcoholics. The approach includes techniques such as open-
ended questions, reflective listening, affirmation, and summarization to help individuals 
express their concerns about change. Evidence of success using this technique in the 
health care setting is useful in improving patient adherence to treatment protocols. 
Primary causative agents for caries being the resident oral flora, the goal of 
therapy is to reduce or control the number of bacteria and not eliminate the flora 
completely. Mechanical removal of plaque by itself has documented to be inadequate 
without use of adjunct chemical methods.  
3.4 Chemical Agents 
 
Most antimicrobial agents used against plaque can be separated on the basis of 
their mode of action. The primary modes are by inhibition of microbial colonization, 
inhibition of microbial growth, disruption of mature plaque and modification of plaque 
biochemistry and ecology[33]. A review of all the chemical agents available is beyond 
the scope of this document, but a few agents with a building evidence base in efficacy 
against caries shall be reviewed. 
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3.4.1 Fluoride 
The evidence base for fluoride significantly decreasing caries risk is well 
established [48, 49]. The mode of action of these products is via fluoroapatite formation, 
remineralization, antimicrobial action and prevention of ionic bonding of pellicle to 
tooth. This effect is however based on the patients overall burden of risk factors. 
Fluorides are available for topical applications mouthrinses, gels, or varnishes; 
dentifrices, or systemic through milk and water fluoridation. Reports in literature suggests  
that topical fluorides used in addition to fluoride toothpaste achieve a modest reduction in 
caries compared to toothpaste used alone [50]. Toothpastes containing fluoride between 
1000-1100 ppm have proven effective while anything below 600ppm have shown to be 
of limited value. The overall reduction in caries reported with their use is between 20-
35% [51]. Fluoride containing oral rinses when used along with brushing twice daily with 
fluoridated toothpaste provided an increase in caries reduction by 10%. While both the 
above mentioned forms of fluoride delivery depend on patient compliance, professional 
application of the fluoride at regular intervals as varnishes (5% NaF) have proven to be 
efficacious [48, 52]. 
Fluoride containing products along with pit and fissure sealants and dietary 
management are considered as the mainstay of caries management. Other non-fluoride 
containing products are also available in the profession. The American Dental 
Association (ADA) Council on Scientific Affairs issued a report in 2011 containing 
clinical guidelines for non-fluoride caries preventive agents. The expert panel's 
recommendations were based on a review of evidence from 71 published articles that 
described 50 randomized controlled trials and 15 nonrandomized studies assessing the 
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effectiveness of various non-fluoride agents in preventing cavities. The review included 
the current available agents such as polyol sugars, chlorhexidine, arginine and probiotics. 
A brief review of these agents follows. 
3.4.2 Xylitol 
Xylitol by chemistry is a “polyol” or “sugar alcohol” (Figure 3). Xylitol along 
with sorbitol are non-fermentable sugars and are used as a sugar replacement in chewing 
gums. 
 The regular use of xylitol as mints or chewing gums is suspected to prevent 
caries by increasing salivary flow through mastication, reducing colonies of MS and 
reducing plaque acidogenesis [53].  This altered pH of the environment possibly aids in 
promoting remineralization of subsurface enamel lesions. Xylitol also has the unique 
ability to select for a MS  population with weakened virulence factors [54, 55]. 
Recommended doses are 5-7 grams of xylitol at a frequency of at least three times per 
day [56], but a lack of consensus however regarding their dosage still exists. 
Additionally, the primary therapeutic agent is available in  many marketable forms such 
as sugar-free chewing gum, lozenges and hard candy including xylitol or polyol 
combinations [57]. The ADA recommends 10 to 20 minutes of chewing of sucrose free 
polyols after meals may prove as adjuncts to reduce incidence of coronal caries.  
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3.4.3 Chlorhexidine 
Chlorhexidine (CHX) has a well-established evidence base as an antiplaque agent 
and is used as a gold standard of treatment. It was first introduced in 1954 as an 
antiseptic. CHX is a strong base with cationic properties and binds to the negatively 
charged bacterial wall causing disturbance of membrane functions. It is effective on both 
gram positive and gram negative bacteria. The effect on gram negative bacteria however 
is weak.  The chemical agent is bacteriostatic in strong concentrations and immediately 
after application. Literature supports reduction in plaque microflora by 80-95% on single 
mouthrinse with 0.2% CHX solution. It also helps convert the pH of the plaque by 
retarding the metabolism of bacteria in low doses by inhibiting bacterial enzymes such as 
glucosyltransferase and phosphophenolpyruvate phosphotransferase [58]. CHX displays 
very high substantive properties and maintains bacteriostatic potency even after 
adsorption on tooth surface. Currently, only mouthrinses containing 0.12 percent CHX 
are marketed in the United States (US).  Two independent reviews of literature concluded 
that the evidence behind efficacy of CHX rinses in reducing caries has been inconclusive 
[59, 60]. Hence CHX rinses alone cannot be recommended for caries control. A 
synergistic effect between fluoride and CHX has been documented on some high risk 
adult populations in literature [61]. However, due to opposite charge on the ions, they 
must be used at least 1 hour apart. CHX is also available in a varnish formulation. The 
expert panel at the ADA Council for Scientific Affairs has found that a 1:1 mixture of 
chlorhexidine/thymol varnish may be efficacious in the prevention of root caries [62]. 
More evidence is required regarding application frequency and long term effect after last 
application. 
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3.4.4 Sodium Hypochlorite 
Sodium hypochlorite solution is frequently used as a disinfectant or a bleaching 
agent. It has broad antimicrobial activity, rapid bactericidal action, relative non-toxicity at 
use concentrations and no staining. Hypochlorite is lethal to most bacteria, fungi and 
viruses. Hypochlorite solutions are extremely reactive and gradually lose strength, so 
fresh solutions should be prepared daily. At high concentrations however, irritation of 
mucous membranes is noticed. Hypochorite is also known to have deproteinization effect 
and has shown to increase the level of Ca
+2
 uptake by carious lesions in experimental in-
vitro specimens [63]. More evidence regarding the anti-cariogenic effect of sodium 
hypochlorite is necessary at this time to validate its use as an effective anti-cariogenic 
agent.  
3.4.5 Arginine 
Recent research has shown the addition of the arginine within dentifrices and food 
products interferes with the initiation and progression of caries [64]. Tooth 
remineralization has also shown to be positively stimulated. The interaction of arginine 
with other flora at this time needs to be investigated further before a definitive disease 
reduction benefit can be observed. 
3.4.6 Probiotics and Genetically Modified Bacteria 
Probiotics are usually live microrganisms (bacteria) which are similar to 
naturally-occurring oral bacteria. These probiotics are currently under investigation since 
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their safety and effectiveness long term have not been tested satisfactorily. Genetically 
modified biomolecules aimed at preferentially targeting cariogenic species in biofilms 
have also been engineered. Ongoing research in these “smart molecules” against specific 
bacteria are encouraging; however further investigation is necessary before they can be 
introduced in the population [65, 66]. 
3.4.7 CariFree®  
CariFree (Oral BioTech, Albany, OR) is a caries risk assessment and treatment 
model based on the CAMBRA approach. Caries risk is determined based on a 
questionnaire and a chair-side measurement of the adenosine triphosphate (ATP) 
bioluminescence (CariScreen Caries Susceptibility Testing) from the plaque present on 
specific sites within the oral cavity. The ATP-driven bioluminescence assays have long 
been used as a quantitative measure of microbial numbers in the packaged food industry 
and more recently for measuring total bacterial mass in dental plaque [67, 68].  Based on 
the level of caries risk, the patient is placed on a treatment regimen. This do-at-home 
treatment includes oral rinses, toothpaste substitutes and chewing gum containing the 
benefits of xylitol, fluoride and pH neutralizing agents. These specific agents help to 
modify the salivary environment and build resistance against acid attack. The CariScreen 
Caries Susceptibility Testing meter can be used chair side and is a validated tool [11, 69]. 
 
   
 
 
 
 
 
 
4 Materials And Methods 
 
This study was a prospective randomized controlled clinical trial to evaluate the 
effectiveness of the CariFree Treatment protocol in reducing caries risk markers on high 
caries risk individuals. During the screening process, subjects were categorized as at risk 
or low risk on the basis of a Caries Risk Assessment (CRA) form and an ATP 
bioluminescence score (CariScreen). Subjects were randomized and placed into either the 
intervention group (receiving CariFree products) or the control group (continued 
conventional oral oral hygiene practices) and followed for 90 days to observe the change 
in their caries risk based on a set of predefined outcome variables, or caries risk markers.  
Saliva and plaque samples were collected at 3 time periods; baseline (visit 1), 30 days 
after baseline (visit 2) and 90 days after baseline (visit 3). 
The research protocol was reviewed and approved by the Institutional Review 
Board (IRB, study #10-1529) of the University of North Carolina at Chapel Hill. Figure 4 
provides a simplified overview of the study design. 
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4.1 Participant Selection  
 
All the participants selected for this study (n=24) were recruited from the UNC 
School of Dentistry Clinics patient pool and UNC student/employee population. Potential 
participants were only approached after IRB review and approval of the study protocol, 
consent forms, and other documents. IRB authorization (and waiver) to access clinic 
schedules and pre-screen patient records in advance of clinic appointments was also 
obtained, so that potential subjects that satisfy inclusion criteria and showed evidence of 
recent restorative work could be approached and invited to participate. Patients were 
screened at the UNC School of Dentistry clinics and only high caries risk subjects were 
recruited. Inclusion and exclusion criteria were as follows: 
Inclusion criteria 
Adults (18-80 years old)  
At least 12 teeth present 
At risk (based on CariScreen scores > 1500 and CRA form) 
Agreement to comply with study protocol 
Able to read, understand, and sign consent form 
Exclusion criteria 
Allergy to study materials components 
Periodontal disease Type IV 
Undergoing antibiotic therapy 
Undergoing radiation therapy 
Subjects participating in any other caries interventional studies 
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A chair-side ATP bioluminescence measurement (CariScreen) and a caries risk 
assessment analysis (CRA form) were performed on all qualifying subjects willing to 
participate in the study. The first 24 subjects with a combined “at risk” reading with 
CariScreen and CRA form were enrolled. Details about using the tools and interpreting 
the reading are provided in the following sections. 
4.1.1 Caries Risk Assessment Form (CRA) 
The CRA form (Appendix A) is a simplified version of the risk assessment form 
developed by at the University of California, San Francisco. It has been further modified 
by others to make it less time consuming for the dental practice setting [7, 45]. The form 
covers disease indicators such as radiographic lesions and white spot lesions along with 
such risk factors as diet, dental hygiene, saliva flow, medications, bacterial population, 
and dental history to identify risk for decay. A subject was categorized as “at risk” with a 
CRA score of 1 or more risk indicators and 2 or more risk factors.  
4.1.2 CariScreen Caries Susceptibility Testing  
4.1.2.1 The CariScreen Caries Susceptibility Testing Swabs 
 Plaque sample was obtained by using a sterile swab (Oral BioTech). The pre- 
packaged swabs were received in a batch of 25 tips. They were stored at 2-8ºC, and 
maintained at room temperature for 15 minutes prior to the measurement. The swabs 
contain the bioluminescence reactive agents in a partition bulb which is released by 
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physically breaking the seal after swabbing. The reactive agents combine with the plaque 
bacteria and a chemical reaction occurs. Chemical energy is converted to light energy 
once placed in the CariScreen Caries Susceptibility Testing Meter and the result is read as 
the intensity of light in Relative Light Units (RLU). The test must be read within 1 
minute of activating. 
Reaction [69]: 
ATP + Luciferin + O2 + Luciferase + Mg2+ ---> AMP +oxyluciferin + PPi + CO2 +                      
light((560 nm)         
 
 
4.1.2.2 The CariScreen Caries Susceptibility Testing Meter 
The meter is a hand held device used to measure the chair-side ATP obtained 
from a sample of the subject’s plaque mass. The meter needs to be calibrated internally 
each time before making a measurement. This is done by turning it on and takes 60 
seconds to be ready to receive a fresh swab sample. 
The procedure for making the measurement is described below and was 
performed as per the manufacturer’s recommendations. 
4.1.3 Plaque Sample Collection  
After calibrating the meter, the swab was removed from its protective tube and 
held close to its tip. A single swipe was made across the lingual surface of the mandibular 
anterior teeth (#22- #27) avoiding contact with soft tissue (Figure 5).  
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4.1.3.1 Sample activation 
The swab tube is secured with one hand, and the thumb and index fingers of other 
hand are used to snap the valve connecting shaft to bulb containing the enzymatic liquid. 
The liquid is squeezed into the tube shaft and allowed to bathe the swab for 10 sec. The 
swab is now activated and must be read in the meter within 1 min. 
4.1.3.2 Meter reading 
The activated CarieScreen device is inserted in to the CarieScreen meter and the 
lid is shut. The device is turned on and counts down till 15 sec. Readings appear on a 
screen in the form of Relative light units (RLU). The luciferase contained in the 
CariScreen system is based on the “flash-type” luminescence signal, with RLU readouts 
peaking at 2 minutes [69]. According to manufacturer’s guidelines they are interpreted 
as: “low risk” 1-1500; “at risk” 1501-9999. This was done within 1 minute of swabbing 
for all samples collected. The swab was then removed and destroyed. 
4.2 Subject Allocation and Randomization Schedule 
 
Once the subject was considered high risk and accepted into the study, all the 
necessary consent and HIPAA forms were reviewed and signed. A stratified block 
randomization schedule was used to assign subjects to intervention or control arms in a 
parallel group design with a 1:1 allocation. A permuted block design (Table 3) developed 
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with a computer random number generator ensured that equal numbers of subjects (n=12) 
were assigned to each arm. This is critical in trials with small numbers of subjects. The 
purpose of randomization was to balance the arms as much as possible with respect to 
known and unknown prognostic factors for dental caries. Within blocks, stratification 
ensured that both groups were balanced on salivary pH (low versus high pH), an 
important characteristic influencing dental caries risk. The salivary pH was measured by 
placing pHion Diagnostic pH Test Strips (pHion Balance, Scottsdale, AZ) in the buccal 
vestibule for 15 seconds. The chairside pH was determined by color transition of the 
strips and read as numerical scores in increments of 0.25. Those subjects 6.5 and above 
were considered low risk and those below were considered as high risk.  Overall, this 
design optimized conditions to test the efficacy of the CariFree intervention on risk of 
dental caries. 
The intervention group received the CariFree Treatment products to be used for 3 
months as per manufacturer recommendations and the control group continued oral 
hygiene practices. Both protocols are described in detail in the following sections. 
4.2.1 CariFree Treatment Protocol 
The 12 subjects in the intervention group were provided with a treatment kit along 
with verbal and written instructions. The protocol is as follows: 
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4.2.1.1 CariFree Treatment rinse 
This rinse is used in the first 30 day of starting treatment. The rinse consists of 
sodium fluoride 0.05%, water, xylitol, menthol, natural flavors, sodium benzoate, 
poloxomer 407, sodium hydroxide, sodium hypochlorite. Instructions include using rinse 
for two times daily for 30 days. Instructions- Mix 5mL from bottle A with 5ml from 
bottle B and rinse with solution for 1 minute and spit out. Wait 30 minutes before eating 
or drinking. 
4.2.1.2 CariFree Maintenance rinse 
The maintenance rinse is used after the 30 day use of the treatment rinse. It 
contains sodium fluoride 0.05%, menthol, natural flavors, polysorbate 20, potassium 
sorbate, sodium benzoate, sodium bicarbonate, water, xylitol. It must be used twice daily 
after brushing and flossing for 60 days. Instructions- Rinse with 10mL of the solution for 
1 minute and spit out. Wait 30 minutes before eating or drinking. 
4.2.1.3 CarieFree Oral neutralizer gel 
The gel contains glycerin, hydrogenated starch hydrolysate, hydroxethyl 
cellulose, menthol, natural flavors, polysorbate 20, potassium sorbate, sodium benzoate, 
sodium bicarbonate, sodium hydroxide, sodium lauryl sulfate, water, xylitol. Instructions-
Use twice daily as a toothpaste supplement for 90 days. 
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4.2.1.4 CariFree Boost 
Boost is an oral spray with a pH close to neutral. It contains purified water, 
xylitol, glycerin, sodium benzoate, calcium hydroxide, natural flavors, and natural colors. 
Instructions-Use 2-3 sprays in mouth as often as needed to relieve dry mouth and 
neutralize acids. Between meals and before bedtime recommended.  
4.2.1.5 CariFree Xylitol gum  
A small sample (6 parts) of chewing gum was included. This did not constitute 
the center of the intervention treatment, but was used more to introduce patients to a 
xylitol based chewing gum. It contains xylitol, gum base, natural flavors, glycerin, gum 
arabic, soy lecithin, calcium acetate, beeswax. Instructions- Chew 2 pieces, 3-5 times 
daily. Recommended after meals or when dry mouth/bad breath occurs. 
4.2.2 Control group 
 
The 12 subjects in the control group were asked to follow conventional oral 
hygiene practices for 90 days. This constitutes brushing 2 times daily with an over the 
counter fluoridated tooth paste and flossing once daily. 
Subjects in both the intervention (n=12) and control group (n=12) had sample 
collection at baseline (visit 1) for their ATP bioluminescence scores and stimulated 
saliva. The measurements were repeated at day 30 (visit 2), and day 90 (visit 3) from the 
baseline records. 
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4.2.3 Stimulated Saliva Collection  
 
For the saliva collection, the participants were given a paraffin wax tablet and 
instructed to chew on it for 5 minutes and saliva was collected and expelled into a sterile 
calibrated collection container up to the 5 minute mark. All samples were collected at the 
same time of the day for each subject. The sample was coded with the unique participant 
identifier and transported on ice to the laboratory for determination of buffering capacity, 
the mutans streptococci (MS) and lactobacilli (LB) counts. The saliva was diluted four-
fold in 0.005N HCl and the final pH determined after ten minutes. The pH values of 4.0 
or less were considered high risk, 4.1 to 4.9 intermediate risk and 5.0 or greater were 
considered normal. Serial 10-fold dilutions of saliva were done and quantitatively plated 
(Spiral PlaterTM model DU2; Spiral Systems Inc.) to DifcoTM Mitis Salivarius Agar 
supplemented with Chapman Tellurite solution and with bacitracin for the selective 
enumeration of MS and to BBLTM LBS Agar for the selective isolation and enumeration 
of Lactobacilli (Figure 6). Counts were performed after 48 hours on a ProtoCOL RGB 
model no. 90000 (Microbiological International Inc.). The limit of detection for bacterial 
counts was 204 CFU/mL of saliva.  MS counts less than 10
4
 CFU/mL and for LB less 
than 10
3
 CFU/mL were considered normally healthy. Total saliva and flow rates were 
also recorded. All samples were destroyed after testing. 
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4.3 Risk Categorization 
 
Categorization of participants into high, intermediate and low risk categories for 
both groups was done based on the ranges in outcome variables as provided in Table 4. 
This was done in order to observe the shift clinical risk categories as the treatment 
proceeded. 
4.4 Adherence to Protocol Evaluation 
 
 
At day 30 (visit 2) and day 90 (visit 3) subjects in both groups were questioned 
about their adherence to protocol via a questionnaire (Appendix B). Subject’s responses 
regarding frequency of oral rinsing, tooth brushing and flossing were recorded. 
4.5 Statistical Analysis 
 
 
Initial exploration using histograms and normal quantile diagnostic plots showed 
that counts of MS and LB at each visit were strongly skewed towards higher values. Zero 
values for LB were substituted with a “1” value prior to computation of base 10 
logarithm transformations. However due to extreme values, log10 transformation failed to 
achieve approximate normality in distribution of these variables. The small sample size 
meant that the data were not robust to violations of assumptions of independence, 
normality and homogeneous variances. Consequently while means, standard deviations, 
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and range for clinical endpoints were reported in descriptive tables and figures, 
differences were tested for statistical significance using two-sample Wilcoxon rank-sum 
(Mann-Whitney) test; a nonparametric analogue of the independent samples t-test. 
Analytic analysis began with a baseline comparison of patient characteristics in 
intervention and control groups. Change from baseline for clinical endpoints was 
calculated by subtracting the current parameter from its baseline value. The strength and 
direction of the relationship between ATP and MS counts was tested using Spearman's 
rank-order correlation. The randomization schedule and statistical analyses of data were 
performed using Stata 12.0 statistical software (StataCorp LP College Station, TX). 
 
   
 
 
 
 
 
 
5  RESULTS 
 
 
 
 
The results of the study are focused on two aims. The primary aim was to 
examine the effectiveness of the CariFree Treatment protocol in reducing caries risk. The 
outcome variables used to measure effectiveness of protocol were: 
i. Plaque ATP bioluminescence scores read in Relative Light Units (RLU) ranging 
from 0-9999. Any score 1500 or below is considered low risk. 
ii. Salivary Buffering capacity read as a laboratory pH measurement. pH 
measurements obtained were ranging from 3.0-6.1 for  the entire study population 
iii. Salivary Mutans Streptococcus (MS) counts  
iv. Salivary Lactobacillus (LB) counts 
The secondary outcome of interest was the correlation between the chairside ATP 
bioluminescence scores and MS counts. 
Table 5 describes the age and characteristics of subjects enrolled in this study, 
including the randomized allocation of intervention and control groups. The age of the 
participants ranged from 22-58 years. The male:female ratio was 5:7 in the intervention 
and 4:8 in the control group. All the outcome variables pre-randomization had no 
statistically significant difference between the two groups. Plaque and saliva samples 
were obtained at baseline, 1 month and 3 months. Only one subject (from the control 
group) was lost at visit 3. 
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Tables 6 and 8 describe the clinical end points of the outcome variables at end of 
1 month and 3 month respectively while Tables 7 and 9 describe the difference in the 
clinical end points at 1 month and 3 months from baseline respectively. The primary end 
point of ATP bioluminescence appears to have a larger variation from baseline in the 
intervention group than control group at both time periods. This change can also be 
appreciated in Figure 7. The mean values in both intervention and control group show a 
tendency to decrease at the 1 month time although both do not reach statistical 
significance. 
While mean values for buffering capacity remained unaltered in the control group 
between baseline and three-month follow-up, the corresponding values for the 
intervention group showed a tendency to increase over time (Figure 8). However these 
differences failed to reach statistical significance. 
 Figures 9 and 10 show the mean MS and LB counts values respectively at 
baseline, 1 month and 3 months for both groups. The mean values of MS and LB in the 
control group remained unaltered during the study, while those for the intervention group 
showed a tendency to increase from baseline at the 1 month measurement, and then 
appeared to decrease resulting in a negative change from baseline at the 3 month (Table 
9). 
Categorization of participants into high, intermediate and low risk categories for 
both groups was further done based on the ranges in outcome variables as provided in 
Table 4. In the control group a reduction was observed in the number of subjects in the 
high risk category based on MS counts from 8 to 3 (62.5%) subjects from baseline to visit 
3 and reduction by 60% in the buffering capacity (Figure 11). In the intervention group 
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the total number of subjects in the high risk category based on ATP scores reduced by 
66.6% (4 out of 6) at visit 3 from baseline (Figure 12). A similar reduction in the high 
risk category of 42.8% in SM counts and 33.3% for buffering capacity from baseline to 
Visit 3 was observed. No remarkable change based on LB counts was observed. 
The adherence to protocol questionnaire (Appendix B) showed that at visit 2 
seven of the twelve subjects (58.3%) randomly assigned to the intervention group 
complied to brushing twice daily. This was a slight improvement from the visit 1 
compliance of 50%. Compliance to rinsing two times daily also improved from 41.6% at 
visit 1 to 66.6 % at visit 2. All of the non-compliant subjects brushed and rinsed at least 
once daily. Flossing once daily had adherence rates of 83.3% at visit 1 and 100% at visit 
2.  
For the subjects assigned to the control group, compliance rates for brushing 
twice daily started at 91% at visit 1 but dropped to 63.6% at visit 2. Daily compliance for 
flossing dropped similarly from 75% to 46% at visit 2. No data was recorded for rinsing, 
since that was not part of protocol for the control group. 
The correlation between the chairside ATP bioluminescence test and the 
laboratory based MS count was determined statistically (Table 11) using the Spearman's 
rank-order correlation tests. At all evaluation times the correlation was poor. 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
6 DISCUSSION 
 
 
 
 
The results of this study show no significant difference between intervention and 
control groups at 3 months post initiation of treatment based on the study outcomes. The 
study outcomes under investigation were ATP bioluminescence scores, buffering 
capacity, Mutans Streptococci and Lactobacillus counts. 
The intervention group received CariFree treatment and maintenance 
mouthrinses, neutralizing gel, boost oral spray and samples of xylitol gum. The treatment 
rinse contains sodium fluoride 0.05%, water, xylitol, sodium hydroxide and sodium 
hypochlorite. The amount of xylitol delivered per dose with this rinse is approximately 
1gm (x 2 times daily). Efficacy of xylitol is dose-dependent, and the minimum amount 
needed to provide a beneficial effect on the plaque biofilm has been shown to be 5-6 
grams/day, divided into three to four doses, for 5-10 minutes per exposure [70]. Hence 
the xylitol from the rinse by itself is insufficient to show therapeutic effect. It could be 
supplemented by oral xylitol mints/chewing gums after reviewing the amount of xylitol 
being delivered through them, since the effects of xylitol on MS plateau between 6.44 g 
and 10.32 g. xylitol/day [71]. 
The combination of agents present in the rinse however might have worked in the 
initial phase to provide a “shock” treatment to the overall bacterial load present in the 
biofilm. This is reflective in the trend observed at visit 1 (1 month) post treatment in the 
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ATP bioluminescence scores. The MS and LB scores appear to follow an opposite trend 
to the ATP scores. This may be explained by the following sequence of events. Sodium 
hypochlorite and its decomposition byproducts such as hypochlorous acid, by nature are 
highly reactive. They combine with the first surface they contact and lose their potency 
rapidly. Considering the inherent protective structure of the biofilm and reduced access to 
antimicrobials [72],  there is a possibility that only the outer layers of the biofilm were 
penetrated by the rinse. This would then facilitate the MS and LB that were buried deeper 
in the tiers to become exposed and more susceptible to collection via the stimulated saliva 
collection technique, causing the apparent trend observed at visit 1. No such trend was 
observed in the control group with the bacterial counts. A small trend towards decline in 
the ATP scores was observed but that might be attributed to an improvement in oral 
hygiene measures in both groups since enrollment in the study. 
At visit 2 (3 months), measurements were made after using the maintenance rinse 
for 60 days. The maintenance rinse contains sodium fluoride 0.05%, water, xylitol and 
sodium hydroxide. The general trend observed for both ATP scores and bacterial counts 
was a reduction in total number in the intervention group suggestive of possible efficacy 
of treatment; however the difference observed did not assume statistical significance. A 
similar trend but to a lesser degree was observed in the control group. 
The buffering capacity of saliva is a measure of the ability to neutralize acid. As 
observed, the buffering capacity seems to have an upward trend as the compliance of the 
patient’s improved (Table 10). There is good evidence that behavior modification and 
counseling can improve adherence to protocol and shift the trends of study outcomes in 
health care settings [73]. A coaching method adopted by the health care provider places 
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them in a position to support and motivate behavior change. During the counseling 
sessions a possible confounding factor came to light and was associated with the poor 
compliance to rinsing in the first month due to the unpleasant taste of the treatment rinse. 
The Rapid ATP Bioluminescence Assays using luciferase enzymes as used in our 
study have been found to have a high correlation with the total plaque mass [10, 11, 67, 
74]. A study looking at the assay of the plaque and saliva samples around orthodontic 
brackets in 14 individuals with ages 11-17 and concluded that ATP-driven 
bioluminescence is highly predictive of the numbers of total oral bacteria and total oral 
streptococci, and by statistical extension, also reflective of the numbers of mutans 
streptococci [11]. The same core group further evaluated the correlation between mutans 
streptococci and ATP Bioluminescence for 33 subjects 7-12 years in age [69]. In this 
study the authors took plaque samples from the mixed dentition at 4 different sites- facial 
of right maxillary first molar, maxillary left central incisor and lingual of left mandibular 
premolar and anterior incisor followed by collection of a stimulated saliva specimen. 
Pearson correlation coefficients of 0.682, 0.611, and 0.548 were identified for total oral 
bacteria, total oral streptococci, and MS, respectively. In our study we were looking 
specifically at the correlation between the total MS counts in saliva and ATP 
Bioluminescence of the plaque mass. Contrary to the findings of the previously 
mentioned study we found a weak to poor correlation between the two. There could be a 
number of reasons to explain this difference. Firstly, as observed by the group in their 
discussion of their study results, a stronger correlation was achieved when using the 
increased statistical power of the larger sample number contained in the composite plaque 
and saliva specimen set. Secondly, the plaque readings in our specimen set were made 
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from only one site as per the manufacturer instructions (the mandibular incisal lingual 
surface) as opposed to different areas around the mouth. Thirdly, no correlation was 
established in this study with the total bacterial counts, which is also a limitation of our 
study. 
While the outcomes have not shown any statistically significant difference 
between the two groups or between the starting and end point of treatment, there is a shift 
in the individual risk categories of the 24 patients observed through the course of the 
treatment suggestive that perhaps the time frame of this study was insufficient to 
determine the efficacy of treatment statistically. 
Due to limitations in time and cost, the total number of subjects in each group was 
12, out of which 1 was lost to follow up in the control group at the third visit. While the 
total sample population was randomized using stratified block randomization, all subjects 
were high caries risk and displayed a wide range in their ATP and bacterial count scores, 
reducing the power of the sample. All attempts were made to motivate the subjects to 
improve their oral hygiene and remain adherent to the protocol but making an objective 
assessment such as recording plaque indices at each visit would have provided useful 
information. Additionally, as a prelude to the 3 month treatment, a run-in phase, to 
monitor the compliance of the subjects might have helped eliminate non-compliant 
subjects. As opposed to some previous studies, the total bacterial counts were not 
calculated as a measure of the effectiveness of the CariFree treatment rinses; only the 
cariogenic species MS and LB were monitored over a period of 3 months [11, 69]. Lastly, 
if this study could be extended to follow the progress of these subjects for a longer 
duration, a statistically significant difference might be appreciated.  
   
 
 
7 CONCLUSIONS 
 
 
 
Within the limitations of this study the following conclusions were drawn: 
1. The CariFree home care protocol did not statistically reduce the caries risk in 
“high” caries risk adults after a 90 day regimen when compared with 
traditional oral hygiene practices. 
2. There was poor agreement between CariScreen ATP bioluminescence assay 
and laboratory streptococcal counts, thereby implying that the reduction in 
overall plaque mass did not correlate with the reduction in percentage MS. 
The CariScreen chair side measurement tool though may prove to be a usual 
adjunct in patient motivation and monitoring progress in plaque control. 
3. While a statistically significant reduction in caries risk was not obtained, there 
was a noticeable shift in the number of subjects in the intervention group from 
a higher risk category to a lesser risk category in all outcomes evaluated 
except LB counts. A similar trend, but to a lesser degree was noticed for the 
control group. 
4. The adherence to protocol was less than 70%  in both groups but a trend was 
noticed towards improvement in buffering capacity with improvement in 
compliance. 
 
   
 
 
FIGURES 
 
 
Fig. 1. Schematic simulating the behavior of similar bacterial cultures containing  
MS and LB, on addition of sugar and (a) controlling pH at 7.0 and (b) 
allowing pH to fall for 6 hours 
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Fig. 2. Adapted schematic of the balance between progressive dental disease at 
one end and protective factors maintaining a low risk [7].  
 
 
 
Fig. 3. Schematic of chemical structure (2R,3r,4S)-Pentane-1,2,3,4,5-pentol 
(Xylitol) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Flowchart depicting the Study Design 
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Used twice daily after brushing 
and flossing from day 30 till 
day 90 
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used twice daily as a  
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days 
 CariFree Boost used 2-3 sprays 
in mouth as often as needed to 
relieve dry mouth and 
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meals and before bedtime 
recommended(90 days) 
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pieces, 3-5 times daily.  
Recommended after meals or 
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(a)
 
(b)
 
Fig. 5. Plaque sample collection with CariScreen swabs from lingual surface of 
mandibular anterior teeth (a and b). 
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(a)
(d)(c)
(b)
 
Fig. 6. Spiral PlaterTM (a) used for spiral plating process (b) over a selective agar 
media (c) for 24h and bacterial counts done by zones (d). 
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Fig. 7. Mean (s.e.) ATP bioluminescence scores for intervention and control 
groups at baseline, and at one month and three months post-randomization  
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Fig. 8. Mean (s.e.) buffering capacity for intervention and control groups at 
baseline, and at one month and three months post-randomization  
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Fig. 9. Mean (s.e.) Mutans streptococci (x 103)  for intervention and control 
groups at baseline, and at one month and three months post-randomization 
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Fig. 10. Mean (s.e.) Lactobacillus (x 103)  for intervention and control groups at 
baseline, and at one month and three months post-randomization  
   
 
 
Fig. 11. Percentage (y axis) and number (table) of  subjects in control group classified in high, intermediate and low risk 
categories (Table 4) at visits 1, 2, and 3 based on (a) ATP bioluminescence scores, (b) buffering capacity , (c) 
Streptococcs Mutans counts and (d) Lactobacillus counts. 
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Fig. 12. Percentage (y axis) and number (table) of  subjects in intervention group classified in high, intermediate and low risk 
categories (Table 4) at visits 1, 2, and 3 based on (a) ATP bioluminescence scores, (b) buffering capacity , (c) 
Streptococcs Mutans counts and (d) Lactobacillus counts. 
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TABLES 
 
Table 1. Risk factors based on clinical examination 
(1) Intermediate or  High Streptococcus Mutans and Lactobacillus counts  
 
 
(2) Inadequate saliva flow (<0.07ml/min stimulated) 
(3) Large number of filled teeth 
(4) Visible heavy plaque 
(5) Recession with exposed  
(6) Defective restorations with open margins 
(7) Fixed/Removable dental prostheses 
(8) Deep pits and fissures 
(9) Noncavitated Lesions 
 
 
 
\ 
 
 
5
0
 
51 
 
 
Table 2. Risk factors based on history 
(1) Existing or recent history of caries 
(2) No dental visit in the past 6 months 
(3) Limited lifetime exposure to water fluoridation 
(4) Brushes once a day or less 
(5) Salivary reducing factors (medication, radiation) 
(6) Frequent snacking between meals (>3 times) 
(7) Health behavior risks (smoking, eating disorders) 
(8) Low socio-economic status 
 
 
(9) Low education levels 
(10) Impaired cognitive ability 
 
 
Table 3. Example of pre-prepared envelopes for randomization of subjects  
 
Envelope 1 Envelope 2 Envelope 3 Envelope 4 Envelope 5 Envelope 6 
Intervention Intervention Control Intervention Control Control 
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Table 4. Risk categories based on accepted values in literature and industry for ATP bioluminescence, buffering capacity, 
Mutans Streptococcus and Lactobacillus counts 
 
 
 
Low Risk Intermediate Risk High Risk 
ATP (RLU) 0-1500 1501-4500 4500-9999 
Buffering capacity- final pH (diluted 1 
to 4 in 0.005N HCl): 5.0-7.0 4.1-4.9 ≤4.0 
Mutans streptococci (MSB counts) < 10
4 
CFU/ml 2x10
4
 to 9x10
4 
CFU/ml 1x10
5 
or greater CFU/ml 
Lactobacillus (Ragosa SL) < 10
3
 CFU/ml 1x10
3
 to 9x10
3
 CFU/ml 1x10
4
 or greater CFU/ml 
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Table 5.  Age, clinical and salivary characteristics of eligible patients in intervention and control groups at enrollment  
Characteristics 
Total sample 
N=24   
Intervention group  
n=12   
Control group  
n= 12  
P-value
(a)
 
 
Mea
n 
Std. 
Dev. 
Min Max  Mean 
Std. 
Dev. 
Min Max  Mean 
Std. 
Dev. 
Min Max  
Age (years) 37.5 10.1 22.0 58.0 
 
38.4 9.6 22.0 51.0 
 
36.5 10.9 23.0 58.0 0.543 
Buffering capacity final pH 4.5 1.2 3.0 6.1  4.2 1.4 3.0 5.8  4.8 1.1 3.0 6.1 0.272 
Chair-side pH 6.5 0.4 5.5 7.0  6.5 0.5 5.5 7.0  6.5 0.4 5.5 7.0 0.881 
ATP (RLU) 
4613
.8 
2770.5 1638.0 9972.0  4824.7 3025.6 1792.0 9832.0  4402.8 2607.3 1638.0 9972.0 0.603 
Mutans streptococci (MSB) (x 10
3
) 517.
4 
975.5 0.5 4600.0  668.6 1315.5 0.5 4600.0  366.2 457.7 0.8 1300.0 0.885 
Lactobacillus (Ragosa SL) (x 10
3
) 
485.
7 
1735.1 0.0 8600.0  853.1 2443.5 0.0 8600.0  118.3 171.0 0.0 490.0 0.340 
Salivary flow rate (mL/minute) 1.4 1.1 0.0 5.0  1.5 1.2 0.5 5.0  1.2 1.0 0.0 3.4 0.644 
 (a)
 P-values test null hypothesis of equivalence between intervention and control groups using two-sample Wilcoxon rank-sum (Mann-Whitney) test  
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Table 6. Clinical endpoints for subjects in intervention and control groups at baseline  
Characteristics 
Intervention group  
n=12   
Control group  
n= 12  
 
P-value
(a)
  
 Mean Std. Dev. Min Max  Mean Std. Dev. Min Max   
Buffering capacity final pH 4.1 1.0 3.0 5.8  4.4 1.1 3.0 5.8  0.531 
Chair-side pH 6.6 0.4 5.8 7.0  6.3 0.4 5.5 6.8  0.063 
ATP (RLU) 2902.8 1931.8 467.0 7470.0  3489.1 1934.1 467.0 6521.0  0.488 
Mutans streptococci (MSB) (x 10
3
) 1211.3 2711.1 0.0 9700.0  393.1 897.6 22.0 3200.0  0.603 
Lactobacillus (Ragosa SL) (x 10
3
) 2277.8 7160.6 0.0 25000.0  89.8 241.0 0.0 850.0  0.067 
Salivary flow rate (ml/minute) 1.3 0.7 0.0 2.3  1.2 0.6 0.2 2.3  0.751 
(a) P-values test null hypothesis of equivalence between intervention and control groups using two-sample Wilcoxon rank-sum (Mann-Whitney) test  
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Table 7. Change (difference from baseline) (a) in primary endpoint and other clinical endpoints, one month post-
randomization  
Characteristics 
Intervention group  
n=12   
Control group  
n= 12  
 P-value
(b)
 
 
Mean 
difference(b) 
Std. Dev.  Mean difference(b) Std. Dev.   
Buffering capacity final pH -0.15 1.48  -0.34 1.10  0.620 
Chair-side pH 0.10 0.34  -0.15 0.45  0.248 
ATP (RLU) -1921.92 2275.04  -913.75 1531.34  0.356 
Mutans streptococci (MSB) (x 10
3
) 542.66 3177.34  26.93 712.81  0.773 
Lactobacillus (Ragosa SL) (x 10
3
) 1424.65 7721.89  -28.42 169.13  0.419 
Salivary flow rate (ml/minute) -0.19 1.17  -0.07 1.21  0.840 
(a)
 Change was computed by subtracting the one month value from the baseline value; positive numbers indicate an increase from baseline. 
(b)
 P-values test null hypothesis of equivalence between intervention and control groups using two-sample Wilcoxon rank-sum (Mann-Whitney) test  
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Table 8. Clinical endpoints for patients in intervention and control groups three months post randomization  
Characteristics 
Intervention group  
n=12   
Control group  
n= 12  
 
P-value
(a)
 
 Mean Std. Dev. Min Max  Mean Std. Dev. Min Max   
Buffering capacity final pH 5.0 1.8 3.1 10.0  4.9 0.9 3.7 6.1  0.782 
Chair-side pH 6.5 0.5 5.5 7.3  6.3 0.5 5.3 6.8  0.193 
ATP (RLU) 2984.6 1655.1 780.0 5800.0  3250.8 1544.6 1605.0 5609.0  0.601 
Mutans streptococci (MSB) (x 10
3
) 237.5 395.5 2.8 1200.0  311.8 542.8 0.0 1700.0  0.902 
Lactobacillus (Ragosa SL) (x 10
3
) 170.6 366.2 0.0 1300.0  46.2 83.5 0.0 290.0  0.369 
Salivary flow rate (ml/minute) 1.8 1.3 0.4 5.4  1.4 0.6 0.4 2.2  0.926 
 (a)
 P-values test null hypothesis of equivalence between intervention and control groups using two-sample Wilcoxon rank-sum (Mann-Whitney) test  
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Table 9. Change (difference from baseline) (a) in primary endpoint and other clinical endpoints, three months post-
randomization  
Characteristics 
Intervention group  
n=12   
Control group  
n= 11  
 P-value
(b)
 
 
Mean 
difference(b) 
Std. Dev.  Mean difference(b) Std. Dev.   
Buffering capacity final pH 0.80 2.28  0.06 0.73  0.339 
Chair-side pH 0.04 0.54  -0.09 0.41  0.489 
ATP (RLU)  -1840.08 2263.85  -1161.36 2223.82  0.242 
Mutans streptococci (MSB) (x 10
3
) -431.11 1081.82  -83.63 797.48  0.806 
Lactobacillus (Ragosa SL) (x 10
3
) -682.50 2492.20  -81.18 212.65  0.902 
Salivary flow rate (ml/minute) 0.28 1.51  0.16 0.93  0.877 
(a)
 Change was computed by subtracting the three month value from the baseline value; positive numbers indicate an increase from baseline. 
(b)
 P-values test null hypothesis of equivalence between intervention and control groups using two-sample Wilcoxon rank-sum (Mann-Whitney) test 
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Table 10.  Mean (95% confidence interval [CI]) change in buffering capacity(a) at three months from baseline, according to 
compliance with home care regime, intervention group (n=12) 
(b) 
 
Sum of compliant 
behaviors 
N subjects 
Mean change in 
buffering capacity 
95%  CI 
0 0 -- -- 
1 1 -0.80 -- 
2 7 0.47 -0.61, 1.55 
3 4 1.77 -2.24, 5.79 
(a)
 Change was computed by subtracting the three month value from the baseline value; positive numbers indicate an increase from baseline. 
(b)
 Compliant behaviors were: tooth brushing 2x daily; CariFree-rinse 2x daily, use of dental floss 1x daily 
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Table 11. Correlation (a) of chairside ATP bioluminescence test (CariScreen) and salivary Streptococcus mutans count 
(CFU/mL of saliva) test at three time points in two treatment groups 
Time Treatment group Rho P-value 
Baseline Intervention 0.105 0.746 
Baseline Control -0.559 0.059 
One month Intervention -0.406 0.190 
One month Control -0.098 0.762 
Three months Intervention -0.406 0.190 
Three months Control -0.098 0.762 
(a) Spearman's rank-order correlation tests the null hypothesis that the ranks of one variable do not covary with the ranks of the other variable 
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Appendix A 
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Appendix B 
 
Adherence to Protocol Questionnaire  
How often do you brush your teeth in a day 
Not at all 
Once 
Twice or more 
How often do you rinse with CariFree mouth 
rinse in a day 
Not at all 
Once 
Twice or more 
How often do you floss your teeth in a day 
Not at all 
Once or more 
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